Cargando…
RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a highly aggressive and metastatic cancer subtype, which is generally untreatable once it metastasizes. We hypothesized that interfering with the Receptor for Advanced Glycation End-products (RAGE) signaling with the small molecule RAGE inhibitors (TTP488/Azel...
Autores principales: | Magna, Melinda, Hwang, Gyong Ha, McIntosh, Alec, Drews-Elger, Katherine, Takabatake, Masaru, Ikeda, Adam, Mera, Barbara J., Kwak, Taekyoung, Miller, Philip, Lippman, Marc E., Hudson, Barry I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344964/ https://www.ncbi.nlm.nih.gov/pubmed/37443146 http://dx.doi.org/10.1038/s41523-023-00564-9 |
Ejemplares similares
-
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
por: Burstein, Aaron H, et al.
Publicado: (2014) -
Azeliragon ameliorates Alzheimer's disease via the Janus tyrosine kinase and signal transducer and activator of transcription signaling pathway
por: Yang, Lijuan, et al.
Publicado: (2021) -
ADAMTS13, TTP and Beyond
por: Zheng, X Long
Publicado: (2012) -
P1612: CALPROTECTIN LEVELS ARE ELEVATED IN CONGENITAL TTP AND IMMUNE TTP AT ADAMTS13 RELAPSE
por: Subhan, Maryam, et al.
Publicado: (2023) -
Hydroxychloroquine, TTP, COVID-19, and SLE
por: Sookaromdee, Pathum, et al.
Publicado: (2021)